Fargo, North Dakota – Fargo based Aldevron has been bought by Danaher Corporation for nearly $9.6 billion, according to an announcement of Danaher Corporation.
Aldevron was founded in 1998 by John Ballantyn and Michael Chambers and the company counts 600 employees.
The company produces high-quality plasmid DNA, mRNA, and proteins for biotechnology and pharmaceutical clients in research, clinical, and commercial applications. Aldevron will run as a separate operational company and brand within Danaher’s Life Sciences department.
“We are thrilled to have Aldevron join Danaher’s Life Sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster,” said Rainer M. Blair, Danaher President and Chief Executive Officer.
“Joining Danaher will help us expand our global reach and harness the power of the Danaher Business System to continue supporting our customers with best-in-class products and services. I’m incredibly excited for Aldevron to take this pivotal next step with Danaher and look forward to the tremendous impact we can make together in the expanding area of genomic medicine,” said Michael Chambers, Aldevron Founder and Executive Chairman.
